Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Related LGND
Spectrum Pharmaceuticals Receives CRL from FDA for EVOMELA for Injection
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689
Related GSK
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
Tracking The Hotchkis & Wiley Value Opportunities Fund - Q3 2015 Update (Seeking Alpha)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA


Related Articles (LGND + GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters